Instrument Inactif

Communiqués Abaco Capital PLC

Actions

GB00B3LXPB43

Sociétés holdings

Communiqués

21/12/17	Oxford Pharmascience : Completion of Demerger, Board Changes & Change of Company Name to Abaco Capital plc	PU
19/12/17	Oxford Pharmascience : Confirmation of Capital Reductions	PU
04/12/17	Oxford Pharmascience : Subdivision of Capital	PU
29/11/17	Oxford Pharmascience : FDA Pre-IND Advice on OXPzero™ Ibuprofen OTC Opportunity	PU
27/11/17	Oxford Pharmascience : Result of General Meeting	PU
20/11/17	Oxford Pharmascience : MPA Advice on OXPzero™ Ibuprofen OTC Opportunity	PU
10/11/17	Oxford Pharmascience : Announcement of demerger	PU
02/10/17	Oxford Pharmascience : MHRA Advice on OXPzero™ Ibuprofen OTC Opportunity	PU
25/09/17	Oxford Pharmascience : Interim results for the six months to 30 June 2017	PU
19/06/17	Oxford Pharmascience : Result of AGM	PU
08/06/17	Oxford Pharmascience : Further Update Regarding OXPzero™ Ibuprofen Programmes	PU
09/05/17	Oxford Pharmascience : Update regarding OXPzero™ Ibuprofen Programmes	PU
31/03/17	Oxford Pharmascience : FDA Pre-IND Feedback on OXPzero™ Ibuprofen Rx programme	PU
10/03/17	Oxford Pharmascience : Final Results for the year ended 31 December 2016	PU
06/03/17	Oxford Pharmascience : OXPzero™ Ibuprofen - Positive Exploratory PK Study Data	PU
20/05/16	Oxford Pharmascience : Shares Magazine Investor Evening Presentation	PU
22/04/16	Oxford Pharmascience : OXP to exhibit at the Master Investor Show 2016	PU
19/04/16	Oxford Pharmascience : Positive Regulatory Advice from MHRA	PU
11/03/16	Oxford Pharmascience : Grant of Share Options	PU
29/01/16	Oxford Pharmascience : Change of Registered Office	PU
25/01/16	Oxford Pharmascience : Entering Partnering Discussions	PU
04/12/15	Oxford Pharmascience : Grant of Share Options	PU
22/09/15	Oxford Pharmascience : Interim results for the 6 months to 30 June 2015	PU
16/09/15	Oxford Pharmascience : Notice of Interim Results	PU
16/07/15	Oxford Pharmascience : Initiation of Pilot Clinical Study	PU